Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
38
RHHBY Quote, Financials, Valuation and Earnings
Last price:
$49.85
Seasonality move
:
2.53%
Day range:
$49.41 - $50.01
52-week range:
$34.75 - $60.85
Dividend yield:
3.23%
P/E ratio:
20.52x
P/S ratio:
4.27x
P/B ratio:
6.76x
Volume:
4M
Avg. volume:
2.6M
1-year change:
26.62%
Market cap:
$314.1B
Revenue:
$74.1B
EPS (TTM):
$2.40
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RHHBY
Roche Holding AG
|
$19.8B | -- | -- | -- | $55.10 |
|
AMGN
Amgen, Inc.
|
$8.6B | $4.75 | 3.22% | 118.8% | $350.41 |
|
AZN
AstraZeneca PLC
|
$14.8B | $1.08 | 4.77% | 35.97% | $135.50 |
|
GILD
Gilead Sciences, Inc.
|
$7.4B | $2.10 | 4.17% | 82.62% | $157.43 |
|
GSK
GSK Plc
|
$11B | $1.23 | 3.52% | 16.98% | $57.48 |
|
NVS
Novartis AG
|
$14.3B | $2.14 | 0.34% | 13.39% | $153.27 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RHHBY
Roche Holding AG
|
$49.85 | $55.10 | $314.1B | 20.52x | $1.59 | 3.23% | 4.27x |
|
AMGN
Amgen, Inc.
|
$347.94 | $350.41 | $184.8B | 24.45x | $2.52 | 2.82% | 5.13x |
|
AZN
AstraZeneca PLC
|
$203.49 | $135.50 | $319.6B | 62.06x | $2.15 | 1.54% | 10.80x |
|
GILD
Gilead Sciences, Inc.
|
$139.71 | $157.43 | $172.7B | 20.51x | $0.82 | 2.29% | 5.93x |
|
GSK
GSK Plc
|
$56.69 | $57.48 | $114.8B | 15.47x | $0.49 | 3.11% | 2.70x |
|
NVS
Novartis AG
|
$154.03 | $153.27 | $291.9B | 21.44x | $4.74 | 3.1% | 5.49x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RHHBY
Roche Holding AG
|
53.53% | 0.497 | -- | 0.88x |
|
AMGN
Amgen, Inc.
|
86.49% | 0.240 | 32.2% | 0.74x |
|
AZN
AstraZeneca PLC
|
37.84% | -0.035 | 10.39% | 0.52x |
|
GILD
Gilead Sciences, Inc.
|
52.94% | 0.640 | 16.78% | 1.23x |
|
GSK
GSK Plc
|
51.97% | 0.232 | 24.37% | 0.44x |
|
NVS
Novartis AG
|
43.4% | 0.246 | 13.43% | 0.75x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RHHBY
Roche Holding AG
|
-- | -- | 14.32% | 28.65% | -- | -- |
|
AMGN
Amgen, Inc.
|
$8.1B | $3.9B | 11.96% | 102.03% | 39.83% | $961M |
|
AZN
AstraZeneca PLC
|
$11.2B | $2.9B | 13.53% | 23.12% | 18.93% | $1.1B |
|
GILD
Gilead Sciences, Inc.
|
$6.3B | $3B | 18.53% | 41.72% | 37.64% | $3.1B |
|
GSK
GSK Plc
|
$8B | $1.3B | 19.46% | 43.01% | 11.2% | $1.4B |
|
NVS
Novartis AG
|
$9.8B | $3.5B | 18.52% | 32.47% | 26.4% | $1.2B |
Roche Holding AG vs. Competitors
-
Which has Higher Returns RHHBY or AMGN?
Amgen, Inc. has a net margin of -- compared to Roche Holding AG's net margin of 13.47%. Roche Holding AG's return on equity of 28.65% beat Amgen, Inc.'s return on equity of 102.03%.
Company Gross Margin Earnings Per Share Invested Capital RHHBYRoche Holding AG-- -- $82.8B AMGNAmgen, Inc.81.91% $2.45 $64.1B -
What do Analysts Say About RHHBY or AMGN?
Roche Holding AG has a consensus price target of $55.10, signalling upside risk potential of 10.53%. On the other hand Amgen, Inc. has an analysts' consensus of $350.41 which suggests that it could grow by 0.75%. Given that Roche Holding AG has higher upside potential than Amgen, Inc., analysts believe Roche Holding AG is more attractive than Amgen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RHHBYRoche Holding AG2 4 1 AMGNAmgen, Inc.9 18 2 -
Is RHHBY or AMGN More Risky?
Roche Holding AG has a beta of 0.507, which suggesting that the stock is 49.273% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.471, suggesting its less volatile than the S&P 500 by 52.947%.
-
Which is a Better Dividend Stock RHHBY or AMGN?
Roche Holding AG has a quarterly dividend of $1.59 per share corresponding to a yield of 3.23%. Amgen, Inc. offers a yield of 2.82% to investors and pays a quarterly dividend of $2.52 per share. Roche Holding AG pays 41.09% of its earnings as a dividend. Amgen, Inc. pays out 66.92% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHBY or AMGN?
Roche Holding AG quarterly revenues are --, which are smaller than Amgen, Inc. quarterly revenues of $9.9B. Roche Holding AG's net income of -- is lower than Amgen, Inc.'s net income of $1.3B. Notably, Roche Holding AG's price-to-earnings ratio is 20.52x while Amgen, Inc.'s PE ratio is 24.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.27x versus 5.13x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHBYRoche Holding AG4.27x 20.52x -- -- AMGNAmgen, Inc.5.13x 24.45x $9.9B $1.3B
-
Which has Higher Returns RHHBY or AZN?
AstraZeneca PLC has a net margin of -- compared to Roche Holding AG's net margin of 15.02%. Roche Holding AG's return on equity of 28.65% beat AstraZeneca PLC's return on equity of 23.12%.
Company Gross Margin Earnings Per Share Invested Capital RHHBYRoche Holding AG-- -- $82.8B AZNAstraZeneca PLC72.19% $0.74 $78.3B -
What do Analysts Say About RHHBY or AZN?
Roche Holding AG has a consensus price target of $55.10, signalling upside risk potential of 10.53%. On the other hand AstraZeneca PLC has an analysts' consensus of $135.50 which suggests that it could fall by -57.25%. Given that Roche Holding AG has higher upside potential than AstraZeneca PLC, analysts believe Roche Holding AG is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings RHHBYRoche Holding AG2 4 1 AZNAstraZeneca PLC1 0 0 -
Is RHHBY or AZN More Risky?
Roche Holding AG has a beta of 0.507, which suggesting that the stock is 49.273% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.346, suggesting its less volatile than the S&P 500 by 65.388%.
-
Which is a Better Dividend Stock RHHBY or AZN?
Roche Holding AG has a quarterly dividend of $1.59 per share corresponding to a yield of 3.23%. AstraZeneca PLC offers a yield of 1.54% to investors and pays a quarterly dividend of $2.15 per share. Roche Holding AG pays 41.09% of its earnings as a dividend. AstraZeneca PLC pays out 15.28% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHBY or AZN?
Roche Holding AG quarterly revenues are --, which are smaller than AstraZeneca PLC quarterly revenues of $15.5B. Roche Holding AG's net income of -- is lower than AstraZeneca PLC's net income of $2.3B. Notably, Roche Holding AG's price-to-earnings ratio is 20.52x while AstraZeneca PLC's PE ratio is 62.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.27x versus 10.80x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHBYRoche Holding AG4.27x 20.52x -- -- AZNAstraZeneca PLC10.80x 62.06x $15.5B $2.3B
-
Which has Higher Returns RHHBY or GILD?
Gilead Sciences, Inc. has a net margin of -- compared to Roche Holding AG's net margin of 27.44%. Roche Holding AG's return on equity of 28.65% beat Gilead Sciences, Inc.'s return on equity of 41.72%.
Company Gross Margin Earnings Per Share Invested Capital RHHBYRoche Holding AG-- -- $82.8B GILDGilead Sciences, Inc.79.65% $1.74 $48.2B -
What do Analysts Say About RHHBY or GILD?
Roche Holding AG has a consensus price target of $55.10, signalling upside risk potential of 10.53%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $157.43 which suggests that it could grow by 12.68%. Given that Gilead Sciences, Inc. has higher upside potential than Roche Holding AG, analysts believe Gilead Sciences, Inc. is more attractive than Roche Holding AG.
Company Buy Ratings Hold Ratings Sell Ratings RHHBYRoche Holding AG2 4 1 GILDGilead Sciences, Inc.18 8 0 -
Is RHHBY or GILD More Risky?
Roche Holding AG has a beta of 0.507, which suggesting that the stock is 49.273% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.386, suggesting its less volatile than the S&P 500 by 61.417%.
-
Which is a Better Dividend Stock RHHBY or GILD?
Roche Holding AG has a quarterly dividend of $1.59 per share corresponding to a yield of 3.23%. Gilead Sciences, Inc. offers a yield of 2.29% to investors and pays a quarterly dividend of $0.82 per share. Roche Holding AG pays 41.09% of its earnings as a dividend. Gilead Sciences, Inc. pays out 46.6% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHBY or GILD?
Roche Holding AG quarterly revenues are --, which are smaller than Gilead Sciences, Inc. quarterly revenues of $8B. Roche Holding AG's net income of -- is lower than Gilead Sciences, Inc.'s net income of $2.2B. Notably, Roche Holding AG's price-to-earnings ratio is 20.52x while Gilead Sciences, Inc.'s PE ratio is 20.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.27x versus 5.93x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHBYRoche Holding AG4.27x 20.52x -- -- GILDGilead Sciences, Inc.5.93x 20.51x $8B $2.2B
-
Which has Higher Returns RHHBY or GSK?
GSK Plc has a net margin of -- compared to Roche Holding AG's net margin of 8.44%. Roche Holding AG's return on equity of 28.65% beat GSK Plc's return on equity of 43.01%.
Company Gross Margin Earnings Per Share Invested Capital RHHBYRoche Holding AG-- -- $82.8B GSKGSK Plc69.38% $0.41 $45.3B -
What do Analysts Say About RHHBY or GSK?
Roche Holding AG has a consensus price target of $55.10, signalling upside risk potential of 10.53%. On the other hand GSK Plc has an analysts' consensus of $57.48 which suggests that it could grow by 1.39%. Given that Roche Holding AG has higher upside potential than GSK Plc, analysts believe Roche Holding AG is more attractive than GSK Plc.
Company Buy Ratings Hold Ratings Sell Ratings RHHBYRoche Holding AG2 4 1 GSKGSK Plc1 6 1 -
Is RHHBY or GSK More Risky?
Roche Holding AG has a beta of 0.507, which suggesting that the stock is 49.273% less volatile than S&P 500. In comparison GSK Plc has a beta of 0.482, suggesting its less volatile than the S&P 500 by 51.834%.
-
Which is a Better Dividend Stock RHHBY or GSK?
Roche Holding AG has a quarterly dividend of $1.59 per share corresponding to a yield of 3.23%. GSK Plc offers a yield of 3.11% to investors and pays a quarterly dividend of $0.49 per share. Roche Holding AG pays 41.09% of its earnings as a dividend. GSK Plc pays out 47.15% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHBY or GSK?
Roche Holding AG quarterly revenues are --, which are smaller than GSK Plc quarterly revenues of $11.5B. Roche Holding AG's net income of -- is lower than GSK Plc's net income of $966.8M. Notably, Roche Holding AG's price-to-earnings ratio is 20.52x while GSK Plc's PE ratio is 15.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.27x versus 2.70x for GSK Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHBYRoche Holding AG4.27x 20.52x -- -- GSKGSK Plc2.70x 15.47x $11.5B $966.8M
-
Which has Higher Returns RHHBY or NVS?
Novartis AG has a net margin of -- compared to Roche Holding AG's net margin of 18.03%. Roche Holding AG's return on equity of 28.65% beat Novartis AG's return on equity of 32.47%.
Company Gross Margin Earnings Per Share Invested Capital RHHBYRoche Holding AG-- -- $82.8B NVSNovartis AG73.44% $1.25 $81.9B -
What do Analysts Say About RHHBY or NVS?
Roche Holding AG has a consensus price target of $55.10, signalling upside risk potential of 10.53%. On the other hand Novartis AG has an analysts' consensus of $153.27 which suggests that it could fall by -2.36%. Given that Roche Holding AG has higher upside potential than Novartis AG, analysts believe Roche Holding AG is more attractive than Novartis AG.
Company Buy Ratings Hold Ratings Sell Ratings RHHBYRoche Holding AG2 4 1 NVSNovartis AG2 5 2 -
Is RHHBY or NVS More Risky?
Roche Holding AG has a beta of 0.507, which suggesting that the stock is 49.273% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.523, suggesting its less volatile than the S&P 500 by 47.695%.
-
Which is a Better Dividend Stock RHHBY or NVS?
Roche Holding AG has a quarterly dividend of $1.59 per share corresponding to a yield of 3.23%. Novartis AG offers a yield of 3.1% to investors and pays a quarterly dividend of $4.74 per share. Roche Holding AG pays 41.09% of its earnings as a dividend. Novartis AG pays out 42.5% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RHHBY or NVS?
Roche Holding AG quarterly revenues are --, which are smaller than Novartis AG quarterly revenues of $13.3B. Roche Holding AG's net income of -- is lower than Novartis AG's net income of $2.4B. Notably, Roche Holding AG's price-to-earnings ratio is 20.52x while Novartis AG's PE ratio is 21.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 4.27x versus 5.49x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RHHBYRoche Holding AG4.27x 20.52x -- -- NVSNovartis AG5.49x 21.44x $13.3B $2.4B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 5
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 5
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 5
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
